
One year to go: NHS leaders set out urgent priorities ahead of 2026 Senedd election
WITH just one year to go until the next Senedd election, NHS leaders in Wales have issued a stark warning to politicians of all parties: without urgent and radical change, the Welsh health and social care system will face an unsustainable future.
The Welsh NHS Confederation, which represents all health boards and trusts in Wales, has published a new report setting out what NHS leaders want from the next Welsh Government. Based on responses from 95 senior NHS figures across the country, the report highlights the urgent need to move away from reactive, short-term measures and towards a long-term strategy focused on prevention, wellbeing, and coordinated action across government departments.
Key among the recommendations is a call for a cross-government strategy to improve health and reduce inequalities, with 87% of NHS leaders backing a national plan that would tackle the wider causes of poor health—such as poverty, housing, education, and employment.
The Confederation warns that without such action, the NHS will struggle to cope with rising demand, driven by factors including an ageing population, an increase in chronic and preventable illnesses, and ongoing workforce shortages. The number of people in Wales living with four or more long-term conditions is projected to double by 2035, placing even greater strain on already overburdened services.
Darren Hughes, director of the Welsh NHS Confederation, said: 'There is only so far the NHS and other public bodies can go in making meaningful, sustainable progress if the right conditions aren't in place.
'Short-term funding cycles make it extremely difficult for organisations to plan effectively, invest wisely, and build the kind of resilient communities we need. If we are serious about reversing the decline in the nation's health, we must focus now on prevention, early intervention and addressing health inequalities at their root.'
He added that demographic trends paint a worrying picture, with the proportion of the population aged 80 and over expected to double between 2000 and 2038. This group already accounts for a disproportionate share of NHS activity.
The Confederation is urging the next government to embrace the principles of the Well-being of Future Generations (Wales) Act 2015, which it says are not being fully realised under current funding arrangements.
While the report has been welcomed by many within the sector, some observers note that successive Welsh Governments—both Labour-led and, in coalition periods, involving Plaid Cymru and the Liberal Democrats—have long acknowledged the importance of prevention, yet struggled to shift funding and policy at the necessary scale.
Critics argue that similar calls have been made repeatedly over the past decade, yet the reality on the ground remains dominated by crisis response and waiting list backlogs. In February 2024, the Welsh Government was forced to issue a £175 million emergency funding package to tackle pressures in emergency care and elective surgery.
Meanwhile, the latest statistics from StatsWales show that as of March 2025, over 750,000 patient pathways remain open—meaning more than one in five people in Wales is waiting for planned treatment or assessment. The British Medical Association Cymru has described the situation as 'deeply worrying,' while acknowledging the immense strain frontline staff are under.
The Confederation's report does not shy away from the scale of the challenge, noting that achieving a shift to prevention will require bold political choices, including long-term investment in public health, closer integration with local government and social care, and a reallocation of resources away from acute care.
Political parties are now beginning to shape their manifestos ahead of the May 2026 Senedd election. Welsh Labour, which has led the Welsh Government since devolution began in 1999, has pledged to maintain a publicly funded, publicly delivered NHS. Plaid Cymru has emphasised the need for a 'National Health and Care Service' to integrate health and social care. The Welsh Conservatives have called for more choice for patients, greater use of technology, and a reduction in management bureaucracy.
The Welsh NHS Confederation said it would engage with all parties over the coming months to ensure that the voice of health and care leaders is heard in shaping the policy agenda.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Glasgow Times
an hour ago
- Glasgow Times
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Glasgow Times
an hour ago
- Glasgow Times
At-home hepatitis C tests identify hundreds with the virus
Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C often shows no signs until serious damage is done. It can be treated, so testing is key to help you help reduce your risk. #WorldHepatitisDay #HepC🔗 — UK Health Security Agency (@UKHSA) July 28, 2025 Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
Rhyl Journal
an hour ago
- Rhyl Journal
At-home hepatitis C tests identify hundreds with the virus
Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C often shows no signs until serious damage is done. It can be treated, so testing is key to help you help reduce your risk. #WorldHepatitisDay #HepC🔗 — UK Health Security Agency (@UKHSA) July 28, 2025 Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'



